Why this matters Taxes shape the final price patients and consumers pay at the counter. New York’s 2024–2025 changes lowered the tax burden on medical cannabis and simplified adult-use taxes—two shifts that can influence affordability in different ways. The medical...
Why you’re hearing so much about Delta-8 Delta-8 THC (usually converted from hemp-derived CBD) remains in legal limbo. In 2025, the FDA continued issuing warning letters over safety/labeling violations, while many states moved to restrict or ban intoxicating hemp...
The headline A new peer-reviewed study following patients with primary insomnia for up to 18 months found sustained improvements in subjective sleep quality and health-related quality of life among those prescribed cannabis-based medicinal products. But it’s an...
The U.S. Department of Justice has proposed moving cannabis from Schedule I to Schedule III. If finalized, this would not legalize adult-use federally—but it would likely remove the punishing 280E tax burden going forward and could gradually lower patient costs in New...
1. Terpenes, 2025’s Medical-Cannabis Headline Open a jar of Burning Bush’s Regenerative OG and you’ll catch citrus, forest-pine, maybe a hint of lavender candy. Those aromas come from terpenes—volatile plant compounds now credited with turning “plain THC” into...
